The most recent PDS Biotechnology (PDSB) insider transaction: John Andrew Dawson (Director) received 22,700 shares as a grant or award on Oct 18, 2026, reported on Form 4 on Oct 21, 2026. So far in the quarter ending Dec 31, 2026, insider holdings showed no net buying or selling.
In the last 12 months, insiders at PDS Biotechnology neither bought nor sold shares on the open market.
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Frank Bedu-Addo | President/Ceo | 690,866 | 0 | 690,866 | 83.1% | 02 Dec, 2022 |
| 2 | Stephen C. Glover | Director | 78,851 | 0 | 78,851 | 9.5% | 03 Mar, 2025 |
| 3 | Gregory Gene Freitag | Director | 61,213 | 0 | 61,213 | 7.4% | 03 Mar, 2025 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 18 Oct, 2026 | John Andrew Dawson | Director | Acquired A | 22,700 | $0.00 | $0 | 22,700 | Direct |
| 18 Oct, 2026 | Bruce Wendel | Director | Acquired A | 22,700 | $0.00 | $0 | 22,700 | Direct |
| 18 Oct, 2026 | Deborah Ramsdell | Director | Acquired A | 22,700 | $0.00 | $0 | 22,700 | Direct |
| 12 Jan, 2026 | Otis W Brawley | Director | Acquired A | 54,876 | $0.00 | $0 | 54,876 | Direct |
| 12 Jan, 2026 | Gregory Gene Freitag | Director | Acquired A | 54,876 | $0.00 | $0 | 54,876 | Direct |
| 12 Jan, 2026 | Kamil Ali-Jackson | Director | Acquired A | 54,876 | $0.00 | $0 | 54,876 | Direct |
| 12 Jan, 2026 | Ilian Iliev | Director | Acquired A | 54,876 | $0.00 | $0 | 54,876 | Direct |
| 12 Jan, 2026 | Frank Bedu-Addo | President/Ceo | Acquired A | 548,782 | $0.00 | $0 | 548,782 | Direct |
| 12 Jan, 2026 | Kirk V. Shepard | Chief Medical Officer | Acquired A | 300,000 | $0.00 | $0 | 300,000 | Direct |
| 12 Jan, 2026 | Spencer D. Brown | Senior Vp, General Counsel | Acquired A | 300,000 | $0.00 | $0 | 300,000 | Direct |
| 12 Jan, 2026 | Stephan Toutain | Chief Operating Officer | Acquired A | 300,000 | $0.00 | $0 | 300,000 | Direct |
| 12 Jan, 2026 | Lars Boesgaard | Chief Financial Officer | Acquired A | 300,000 | $0.00 | $0 | 300,000 | Direct |
| 12 Jan, 2026 | Gregory Conn | Chief Scientific Officer | Acquired A | 150,000 | $0.00 | $0 | 150,000 | Direct |
| 12 Jan, 2026 | Stephen C. Glover | Director | Acquired A | 54,876 | $0.00 | $0 | 54,876 | Direct |
| 12 Jun, 2025 | Stephan Toutain | Chief Operations Officer | Acquired A | 150,000 | $0.00 | $0 | 150,000 | Direct |
| 12 Jun, 2025 | Kirk V. Shepard | Chief Medical Officer | Acquired A | 150,000 | $0.00 | $0 | 150,000 | Direct |
| 12 Jun, 2025 | Lars Boesgaard | Chief Financial Officer | Acquired A | 150,000 | $0.00 | $0 | 150,000 | Direct |
| 11 Jun, 2025 | Ilian Iliev | Director | Acquired A | 22,700 | $0.00 | $0 | 22,700 | Direct |
| 11 Jun, 2025 | Kamil Ali-Jackson | Director | Acquired A | 22,700 | $0.00 | $0 | 22,700 | Direct |
| 11 Jun, 2025 | Gregory Gene Freitag | Director | Acquired A | 22,700 | $0.00 | $0 | 22,700 | Direct |